BioXcel Therapeutics (BTAI)
(Delayed Data from NSDQ)
$2.31 USD
+0.19 (8.73%)
Updated May 9, 2024 04:00 PM ET
After-Market: $2.30 -0.01 (-0.22%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
BioXcel Therapeutics, Inc. [BTAI]
Reports for Purchase
Showing records 101 - 107 ( 107 total )
Company: BioXcel Therapeutics, Inc.
Industry: Unclassified
BXCL701 Principal Mechanism Highlighted in Peer-Reviewed Publication; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Unclassified
Neuroscience Clinical Advisory Board Formed; Further Milestones Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Unclassified
Positive Phase 1b IV Dexmedetomidine Study Data to Support BXCL501 Development; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Unclassified
Chief Medical Officer Formally Appointed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Unclassified
BXCL701 ASCO Poster Presentation Provides Hints of Intriguing Combo Activity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Unclassified
1Q 2018 Results Reported; Solid Cash Position; ASCO Catalyst Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Unclassified
Supercharging Drug Development via Artificial Intelligence; Initiating at Buy and $25 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R